OakChart

Sutro Biopharma Inc

STROHealthcare·Biotechnology·USA·Micro·NASD·Nov 10 • 3:59 PM ET

10.170.00 (0.00%)
2026-11-11 14:40 CET
Market cap
168.63 USD m
Revenue, TTM
45.70 USD m
Net income, TTM
-180.64 USD m
Free cash flow, TTM
-145.62 USD m
EPS diluted, TTM
-17.41
P/E
-
Compare

Price

STRO against its 20, 50 and 200-day averages
2050200miss
10.0020.0030.0040.001.4M2.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26STROclose 10.1720-day 9.9850-day 13.82200-day 22.8410.17

76.8% under 43.85 on 15 May 2026. Last 15 sessions, 45.5% high to low

Profile

STRO
52-week range, 8% of the way up
7.1543.85

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

IndexRUT
Employees137
IPOSep 27, 2018
Beta1.52
ATR, 14d0.98
Rel volume0.00
Short float15.71%
Insider own13.34%
Inst own93.27%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap168.63M
Enterprise Value254.13M
Income-180.64M
Sales45.70M
Book/sh-6.23
Cash/sh9.91
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees137
IPOSep 27, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S3.69
P/B-
P/C1.03
P/FCF-
EV/EBITDA-
EV/Sales5.56
Quick Ratio3.32
Current Ratio3.32
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-17.41
EPS next Y-6.39
EPS next Q-1.64
EPS this Y64.86%
EPS next Y19.15%
EPS next 5Y33.87%
EPS past 3/5Y1.45% -17.92%
Sales past 3/5Y14.78% 19.12%
EPS Y/Y TTM30.97%
Sales Y/Y TTM-56.25%
EPS Q/Q-71.03%
Sales Q/Q-84.57%
EarningsAug 12 BMO
EPS/Sales Surpr.-6.20% -17.74%

Ownership

Insider Own13.34%
Insider Trans0.00%
Inst Own93.27%
Inst Trans6.78%
ROA-79.08%
ROE-1810.01%
ROIC-129.15%
Gross Margin86.73%
Oper. Margin-288.52%
Profit Margin-395.25%
SMA201.92%
SMA50-26.42%
SMA200-55.48%
Trades-

Technical

Shs Outstand16.58M
Shs Float14.37M
Short Float15.71%
Short Ratio6.99
Short Interest2.26M
52W High43.85 -76.81%
52W Low7.15 42.24%
Volatility10.11% 9.82%
ATR (14)0.98
RSI (14)41.63
Beta1.52
Rel Volume0.00
Avg Volume322.73K
Volume0

Performance

Perf Week6.94%
Perf Month-23.42%
Perf Quarter-52.25%
Perf Half Y-75.14%
Perf YTD-12.10%
Perf Year26.16%
Perf 3Y-51.11%
Perf 5Y-95.29%
Perf 10Y-
Recom1.29
Target Price47.23
Prev Close10.17
Price10.17
Change %0.00%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 30, 2026ResumedWWells FargoOverweight$49+381.8%
Aug 07, 2026InitiatedSStifelBuy$48+372.0%
Jun 11, 2026ResumedTTruistBuy$50+391.6%
May 28, 2026InitiatedBBarclaysOverweight$56+450.6%
May 15, 2026UpgradeWWedbushNeutral → Outperform$60+490.0%
Apr 30, 2026InitiatedMMizuhoOutperform$50+391.6%
Apr 07, 2026InitiatedLLeerink PartnersOutperform$38+273.6%
Mar 24, 2026UpgradeWWells FargoEqual Weight → Overweight$27+165.5%
Mar 24, 2026UpgradeHH.C. WainwrightNeutral → Buy$28+175.3%
Jan 20, 2026UpgradeCCitizens JMPMkt Perform → Mkt Outperform$23+126.2%

Peers

Mkt cap
TickerCompanyMkt cap
WHWKWhitehawk Therapeutics Inc181.75M
MGNXMacrogenics Inc154.15M
KYNBKyntra Bio Inc14.46M
CRBPCorbus Pharmaceuticals Holdings Inc77.36M
PYXSPyxis Oncology Inc194.96M
ZYMEZymeworks BC Inc2.22B
BCYCBicycle Therapeutics Plc ADR186.57M
CTMXCytomX Therapeutics Inc433.83M
ADAGAdagene Inc ADR137.64M
VRXAVeraxa Biotech AG158.07M

Insider trading

12 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Gerber Hans-PeterCHIEF SCIENTIFIC OFFICERSep 18 '26Option Exercise0.003,750013,712Sep 22 04:09 PM
Chow Gregory K.CFOJun 02 '26Option Exercise0.002,50004,725Jun 02 04:16 PM
Pauling DavidChief Admin. Ofcr. & GCMar 04 '26Option Exercise0.00675010,025Mar 06 04:25 PM
Chung JaneChief Executive OfficerMar 04 '26Option Exercise0.00788021,567Mar 06 04:21 PM
Pauling DavidChief Admin. Ofcr. & GCMar 02 '26Option Exercise0.002,356010,320Mar 03 06:59 PM
Pauling DavidChief Admin. Ofcr. & GCMar 01 '26Option Exercise0.001,34208,515Mar 03 06:59 PM
Gerber Hans-PeterCHIEF SCIENTIFIC OFFICERMar 02 '26Option Exercise0.002,843010,688Mar 03 06:56 PM
Gerber Hans-PeterCHIEF SCIENTIFIC OFFICERMar 01 '26Option Exercise0.001,12508,308Mar 03 06:56 PM
Chung JaneChief Executive OfficerMar 02 '26Option Exercise0.007,750023,558Mar 03 06:48 PM
Chung JaneChief Executive OfficerMar 01 '26Option Exercise0.003,188017,079Mar 03 06:48 PM
BARBARA LEYMANFormer OfficerJan 20 '26Proposed Sale14.678,929130,962Jan 20 04:17 PM
Chung JaneChief Executive OfficerDec 12 '25Option Exercise0.002,500014,785Dec 16 08:47 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
IWMiShares Russell 2000 Index FundAUM: 78.30B
VXFVanguard Extended Market Index ETFAUM: 30.61B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.85B
VTWOVanguard Russell 2000 Index ETFAUM: 16.97B
IWNiShares Russell 2000 Value ETFAUM: 14.17B
VHTVanguard Health Care ETFAUM: 21.40B
VFMOVanguard U.S. Momentum Factor ETFAUM: 1.83B
IWCiShares Micro-Cap ETFAUM: 1.23B
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.65B

News

latest 14 of 206
  • Sutro Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors (GlobeNewswire) -6.50%
  • Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference (GlobeNewswire) -6.94%
  • Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development (GlobeNewswire)
  • STRO Stock Plummets 15% What Drove The Selloff? (Stocktwits) -14.94%
  • Loading…
  • Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study (GlobeNewswire)
  • SpaceX upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly) +5.09%
  • Barclays initiates oncology-focused biotechs with positive outlook (Investing.com)
  • Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
  • Meta downgraded, Qualcomm upgraded: Wall Street's top analyst calls (The Fly)
  • Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026 (GlobeNewswire)
  • Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last? (Quartz) +5.21%
  • Arm downgraded, Arista Networks upgraded: Wall Street's top analyst calls (The Fly) +7.35%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-12-2.330-2.194-2.3309.8411.9614
2026Q12026-05-14-2.940-2.736-2.94214.528.8911
2025Q42026-03-23-5.290-8.163-5.44711.659.2610
2025Q32025-11-06-6.700-3.945-6.6999.6910.1410
2025Q22025-08-07-1.400-3.824-1.36063.7515.8410
2025Q12025-05-08-9.100-6.426-9.14117.4011.619
2024Q42025-03-13-8.300-8.304-8.77814.8012.1511
2024Q32024-11-13-5.900-7.346-5.9478.5215.2911
2024Q22024-08-13-5.900-7.916-5.91225.7121.0210
2024Q12024-05-13-9.500-9.216-9.47213.0112.0710
2023Q42024-03-265.200-2.7135.092113.7357.369
2023Q32023-11-13-8.100-7.360-8.13316.9213.0110
2023Q22023-08-10-6.400-7.325-6.38510.4112.568
2023Q12023-05-15-8.500-7.837-8.52312.6712.138
2022Q42023-03-30-5.900-6.212-6.0928.6214.528
2022Q32022-11-08-3.700-2.888-3.72325.1535.718

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-24.300-24.826-24.28042.7441.38
2020FY-9.9000.825-9.86342.7242.67
2021FY-22.900-22.331-22.88461.8862.36
2022FY-23.500-25.111-23.49467.7768.38
2023FY-17.800-25.344-17.751153.7397.35
2024FY-29.600-28.982-29.60662.0459.04
2025FY-22.490-17.807-22.490102.4899.18
2026FY--7.903--50.97
2027FY--6.390--34.23
2028FY--6.503--38.17
2029FY--6.214--38.20
2030FY--5.733--74.73

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-28121014.102.5050.00
2026Q3S2026-10-27122014.102.5050.00
2026Q3S2026-10-26121013.602.5050.00
2026Q3S2026-10-21123413.602.5050.00
2026Q3S2026-10-15123413.612.5050.00
2026Q3S2026-08-14123413.612.5050.00
2026Q3S2026-08-12122412.812.5050.00
2026Q3S2026-08-1111009.660.0015.11
2026Q3S2026-08-0511019.660.0015.11
2026Q3S2026-08-04100110.230.0015.11
2026Q3S2026-07-29101110.230.0015.11
2026Q3S2026-06-25103110.230.0015.11
2026Q3S2026-06-10114110.400.0015.11
2026Q3S2026-05-28104110.240.0015.11

Estimate history

EPS, annual-8.617-61.326-24.28-9.863-22.884-23.494-17.751-29.606-22.487-17.4136
Period201720182019202020212022202320242025TTM
EPS, quarterly-5.912-5.947-8.778-9.141-1.36-6.699-5.447-2.942-2.325
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual51.74138.41942.73642.72261.8867.772153.73162.043102.48445.7
Period201720182019202020212022202320242025TTM
Sales, quarterly25.7068.5214.80917.39963.7459.69311.64714.5239.839
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual2.2852.2852.314.5754.6335.756.1018.2538.58416.576
Period201720182019202020212022202320242025MRQ
Shares, quarterly8.1868.248.2538.4358.4728.518.58416.56716.576
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue45.70102.4862.04153.7367.7761.8842.7242.7438.42
Cost of Goods Sold Incl. D&A6.067.327.226.828.299.77---
Gross Profit39.6495.1654.83146.9159.4852.11---
Selling, General and Administrative Excl. Other171.50200.11293.28236.19188.43150.63109.4893.4371.10
Research and Development144.74166.42252.04180.43137.17104.4076.9665.6154.26
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-131.86-104.95-238.45-89.28-128.94-98.52-71.06-55.47-37.22
Interest Expense38.5538.2137.4313.873.353.144.084.351.60
Unusual Expense14.1953.410.00-9.92-12.134.45-41.50--0.84
Net Income Before Taxes-180.73-191.18-225.10-88.60-116.70-105.54-32.13-55.74-35.32
Income Taxes-0.10-0.092.3618.192.500.000.000.000.00
Consolidated Net Income-180.64-191.09-227.46-106.79-119.20-105.54-32.13-55.74-35.32
Net Income From Continuing Operations-180.64-191.09-227.46-106.79-119.20-105.54-32.13-55.74-35.32
Net Income-180.64-191.09-227.46-106.79-119.20-105.54-32.13-55.74-35.32
EPS (Recurring)-10.30-18.09-29.61-18.90-25.17-22.21-18.78-24.28-61.33
EPS (Basic, Before Extraordinaries)-17.41-22.49-29.61-17.75-23.49-22.88-9.86-24.28-61.33
EPS (Diluted)-17.41-22.49-29.61-17.75-23.49-22.88-9.86-24.28-61.33
EBITDA-125.80-97.63-231.24-82.46-120.66-88.75-66.76-50.69-32.68
Non-Operating Income (Expense)3.875.4050.784.633.460.581.514.073.51
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.6811.0719.5019.6820.7823.2411.9210.312.87
Price To Sales Ratio12.040.962.281.686.0511.0916.555.911.35
Gross Margin86.7392.8588.3795.5787.7784.21---
Operating Margin-288.52-102.41-384.34-58.07-190.26-159.22-166.32-129.79-96.89
Net Margin-395.25-186.45-366.62-69.47-175.89-170.55-75.20-130.44-91.93
Shares Outstanding16.588.588.256.105.754.634.582.312.28
Market Capitalization168.63168.63151.85261.26441.42689.35993.28254.09206.09

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue9.8414.5211.659.6963.7417.4014.818.52
Cost of Goods Sold Incl. D&A1.261.281.621.901.901.901.871.80
Gross Profit8.5813.2410.027.7961.8415.5012.946.72
Selling, General and Administrative Excl. Other38.2642.8643.6846.6946.7762.9778.2074.64
Research and Development31.7036.5536.6439.8538.3351.6071.0462.11
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-29.69-29.61-33.66-38.9015.08-47.47-65.26-67.92
Interest Expense9.869.479.559.679.659.348.697.91
Unusual Expense0.200.044.399.5618.4221.040.000.00
Net Income Before Taxes-38.53-38.50-46.84-56.86-11.52-75.97-70.09-48.79
Income Taxes0.00-0.01-0.080.00-0.020.002.350.00
Consolidated Net Income-38.53-38.48-46.76-56.86-11.50-75.97-72.44-48.79
Net Income From Continuing Operations-38.53-38.48-46.76-56.86-11.50-75.97-72.44-48.79
Net Income-38.53-38.48-46.76-56.86-11.50-75.97-72.44-48.79
EPS (Recurring)-2.32-2.94-5.09-5.910.17-7.37-8.78-5.95
EPS (Basic, Before Extraordinaries)-2.33-2.94-5.45-6.70-1.36-9.14-8.78-5.95
EPS (Diluted)-2.33-2.94-5.45-6.70-1.36-9.14-8.78-5.95
EBITDA-28.43-28.34-32.03-37.0016.98-45.57-63.39-66.12
Non-Operating Income (Expense)1.220.620.751.271.481.893.8627.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.591.231.311.554.165.544.676.54
Price To Sales Ratio12.043.270.970.700.580.812.451.76
Gross Margin87.1791.2086.0680.4097.0289.0887.3978.88
Operating Margin-301.73-203.91-288.98-401.3323.65-272.84-440.66-797.17
Net Margin-391.64-264.99-401.49-586.58-18.04-436.62-489.18-572.62
Shares Outstanding16.5816.578.588.518.478.438.258.24
Market Capitalization168.63412.6998.5773.9060.4854.88151.85285.09

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments141.43316.89375.62334.36197.94368.14117.86204.4922.02
Short Term Receivables3.988.6236.087.1212.455.566.302.491.62
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets5.5217.809.8511.678.124.494.412.961.99
Total Current Assets150.93343.31421.54353.15218.51378.18128.57209.9525.63
Net Property, Plant & Equipment21.5535.8744.7651.0651.5912.949.6310.9314.00
Total Investments and Advances0.860.860.000.0069.650.8715.620.010.01
Long-Term Note Receivable-------0.000.21
Intangible Assets--------0.00
Other Assets0.497.174.442.731.662.122.542.241.13
Total Assets173.83387.21470.74406.94341.41394.11156.37223.1440.98
Short Term Debt Incl. Current Port. of LT Debt7.787.4810.4817.0910.410.001.004.7214.56
Accounts Payable7.5710.479.444.8011.335.545.583.062.90
Income Tax Payable0.000.0215.16------
Other Current Liabilities59.78113.9258.6644.6620.0024.0526.3828.6414.49
Total Current Liabilities75.13131.8993.7566.5541.7429.6032.9736.4231.96
Long Term Debt227.43196.48172.2733.3446.9624.558.8810.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities3.7214.2355.0790.000.157.9216.7445.1815.31
Total Liabilities306.28342.61321.09189.9088.8462.0658.5891.6047.27
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00102.50
Common Equity-132.4544.60149.65217.05252.56332.0597.79131.54-108.79
Total Shareholders Equity-132.4544.60149.65217.05252.56332.0597.79131.54-6.29
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-132.4544.60149.65217.05252.56332.0597.79131.54-6.29
Total Liabilities & Stockholders Equity173.83387.21470.74406.94341.41394.11156.37223.1440.98
Book Value Per Share-15.435.4024.5337.7554.5272.5842.3357.57-47.62
Tangible Book Value Per Share-15.435.4024.5337.7554.5272.5842.3357.57-47.62
Full-Time Employees137338302295239191168158128
Price to Book Ratio-1.633.402.331.922.732.992.601.57-1.40
Return on Assets-68.12-53.02-24.34-31.86-28.70-11.67-29.38-26.74-35.65
Return on Equity--234.19-58.25-50.77-36.11-14.95-48.62-56.39-712.95
Return on Invested Capital-201.20-94.35-33.17-47.61-35.24-9.01-52.26-24.95-
Quick Ratio2.012.604.505.315.2412.783.905.760.80
Current Ratio2.012.604.505.315.2412.783.905.760.80

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-180.64-191.09-227.46-106.79-119.20-105.54-32.13-55.74-35.32
Depreciation6.067.327.226.828.299.774.304.784.54
Other Funds (Non Cash)50.7956.9319.8022.7410.0631.71-28.489.210.85
Funds from Operations-123.78-126.83-200.44-77.24-100.86-64.06-56.32-41.76-29.92
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-21.39-50.408.90-34.38104.41-17.62-11.49-23.2642.61
Cash from Operating Activities-145.17-177.23-191.54-111.623.55-81.68-67.80-65.0212.68
Capital Expenditures-0.45-1.70-3.10-4.32-7.86-15.32-7.13-3.48-1.56
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments33.2346.71221.610.39-27.17-82.007.64-47.65-78.71
Purchase of Investments-246.53-264.95-461.52-460.30-216.67-248.73-130.74-196.23-81.46
Sale Or Maturity of Investments279.76311.66683.13460.69189.50166.73138.38148.582.75
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.010.010.090.000.08
Cash from Investing Activities32.7945.01218.51-3.92-35.02-97.310.60-51.13-80.19
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock102.950.3898.6514.3458.154.25254.561.11169.58
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock102.950.3898.6514.3458.154.25254.561.11169.58
Proceedsfrom Stock Options102.780.3798.3814.0257.881.76252.700.93169.18
Issuance or Reduction of Debt, Net0.000.00-4.08123.71-9.380.0015.00-5.000.00
Change in Long Term Debt0.000.00-4.08123.71-9.380.0015.00-5.000.00
Issuance of Long Term Debt0.000.000.00136.210.000.0025.000.000.00
Reduction of Long Term Debt0.000.00-4.08-12.50-9.380.00-10.00-5.000.00
Net Financing Active Other Cash Flow-0.25-0.33-0.51-0.49-0.46-0.99-0.31-0.301.21
Other Financing Activities Uses-0.25-0.33-0.51-0.49-0.46-0.99-0.31-0.300.00
Cash from Financing Activities102.690.0494.05137.5548.313.26269.25-4.18170.78
Net Change in Cash-9.69-132.17121.0222.0116.84-175.74202.05-120.34103.28
Free Cash Flow-145.62-178.93-194.64-115.93-4.31-97.00-74.93-68.5011.13
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow--------4.67
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments164.35202.56141.43167.59205.13248.97
Short Term Receivables5.8012.483.983.928.0013.56
Inventories0.000.000.000.000.000.00
Other Current Assets5.505.935.5210.6018.5024.88
Total Current Assets175.65220.97150.93182.11231.63287.41
Net Property, Plant & Equipment16.8219.0721.5526.6929.8233.08
Total Investments and Advances0.860.860.860.860.860.86
Intangible Assets---0.00--
Other Assets1.131.090.490.000.050.09
Total Assets194.46241.99173.83209.66262.36321.43
Short Term Debt Incl. Current Port. of LT Debt6.667.607.787.968.067.76
Accounts Payable3.365.497.577.034.318.18
Income Tax Payable--0.00---
Other Current Liabilities42.8857.7359.7856.9061.88117.10
Total Current Liabilities52.9070.8175.1371.8974.25133.05
Long Term Debt243.19235.14227.43219.58211.62203.93
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities1.692.933.725.458.6010.26
Total Liabilities297.78308.88306.28296.93294.47347.24
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-103.32-66.89-132.45-87.27-32.11-25.81
Total Shareholders Equity-103.32-66.89-132.45-87.27-32.11-25.81
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-103.32-66.89-132.45-87.27-32.11-25.81
Total Liabilities & Stockholders Equity194.46241.99173.83209.66262.36321.43
Book Value Per Share-6.23-4.04-15.43-10.25-3.79-3.06
Tangible Book Value Per Share-6.23-4.04-15.43-10.25-3.79-3.06
Full-Time Employees128-137178244269
Price to Book Ratio-1.63-1.61-1.13-0.85-1.88-2.13
Return on Assets-79.08-54.53-68.12-65.54-55.55-67.66
Return on Equity----1,810.01-347.64-679.15
Return on Invested Capital-27.55-22.87-49.24-42.97-6.41-42.65
Quick Ratio3.323.122.012.533.122.16
Current Ratio3.323.122.012.533.122.16

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-38.53-38.48-46.76-56.86-11.50-75.97
Depreciation1.261.281.621.901.901.90
Other Funds (Non Cash)12.7611.8914.0212.1215.4615.33
Funds from Operations-24.52-25.32-31.11-42.845.86-58.74
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-13.78-16.944.684.65-50.58-9.15
Cash from Operating Activities-38.29-42.26-26.43-38.19-44.72-67.88
Capital Expenditures0.00-0.01-0.18-0.25-0.09-1.17
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments19.36-45.2518.8940.242.67-15.08
Purchase of Investments-27.85-124.70-4.04-89.94-28.59-142.38
Sale Or Maturity of Investments47.2179.4522.93130.1831.26127.30
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities19.36-45.2618.7039.992.58-16.26
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.42103.230.000.130.000.25
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.42103.230.000.130.000.25
Proceedsfrom Stock Options-0.47103.130.000.130.000.25
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.16-0.07-0.03-0.06-0.18
Other Financing Activities Uses0.00-0.16-0.07-0.03-0.06-0.18
Cash from Financing Activities-0.42103.08-0.060.10-0.060.07
Net Change in Cash-19.3515.55-7.801.90-42.20-84.08
Free Cash Flow-38.29-42.27-26.62-38.44-44.81-69.06

Revenue breakdown

Total Biological Products, (No Diagnostic Substances) revenue2024: 62.04M 2025: 102.48M
United States2024: 62.04M 2025: 102.48M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.71%2.3M14.4M310.94K
2026-10-1513.65%2.0M14.4M297.75K
2026-09-3012.86%1.8M14.4M306.43K
2026-09-1514.45%2.1M14.4M355.36K
2026-08-3112.59%1.8M14.4M336.21K
2026-08-1412.91%1.9M14.4M370.91K
2026-07-3112.20%1.7M14.3M349.14K
2026-07-1511.56%1.7M14.3M346.36K
2026-06-309.53%1.4M14.3M324.71K
2026-06-156.45%0.9M14.3M268.34K
2026-05-295.26%0.8M14.3M258.00K
2026-05-158.35%1.2M14.3M211.26K
2026-04-306.13%1.0M15.9M200.32K
2026-04-154.70%0.7M15.9M177.01K
2026-03-314.17%0.6M15.4M155.74K
2026-03-133.51%0.5M15.2M131.16K
2026-02-273.41%0.5M15.2M127.12K
2026-02-134.25%0.6M15.2M120.99K
2026-01-307.50%0.6M7.9M110.84K
2026-01-156.70%0.5M7.9M132.81K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call7.501.004.900.006.1670.000.000.839-0.0490.004
call10.000.004.200.656.52540.000.000.709-0.1900.006
call12.500.004.900.457.6067290.000.677-0.2320.006
call15.000.000.450.305.0863.000.000.517-0.1720.007
call17.500.004.900.002.8860.000.000.199-0.0690.005
call20.000.002.000.456.19318.000.000.476-0.2090.007
call22.500.001.501.053.7445.000.000.171-0.0810.004
call25.000.000.959.004.1340.000.000.163-0.0860.004
call30.000.000.701.524.8168.000.000.201-0.1140.005
call35.000.004.9011.704.9268.000.000.142-0.0950.004
call40.000.005.001.005.4256.000.000.138-0.1010.004
call45.000.004.9010.245.5705.000.000.132-0.1020.004
call50.000.004.900.005.8300.000.000.128-0.1050.004
call55.000.004.900.006.0600.000.000.125-0.1070.004
call60.000.004.900.006.2670.000.000.123-0.1090.004
put7.500.000.400.502.33657.000.00-0.161-0.0480.004
put10.000.004.000.006.4900.000.00-0.291-0.1880.006
put12.500.504.904.005.0432.000.00-0.323-0.2310.006
put15.002.557.004.605.2715.000.00-0.774-0.0620.005
put17.505.009.502.755.9030.000.00-0.801-0.0700.005
put20.007.5012.003.756.4120.000.00-0.818-0.0760.004
put22.5010.0014.500.006.8380.000.00-0.829-0.0800.004
put25.0012.5017.007.657.2030.000.00-0.837-0.0840.004
put30.0017.5022.008.307.8050.000.00-0.849-0.0890.004
put35.0022.5027.000.008.2900.000.00-0.857-0.0940.004
put40.0027.5032.000.008.6960.000.00-0.862-0.0970.004
put45.0032.5037.000.009.0430.000.00-0.867-0.1000.004
put50.0037.5042.0027.409.3460.000.00-0.870-0.1020.004
put55.0042.5047.000.009.6160.000.00-0.873-0.1040.003
put60.0047.5052.000.009.8580.000.00-0.876-0.1050.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09SCHEDULE 13GSEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-07-30SCHEDULE 13GSEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-088-KCurrent report2026-06-05SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13GSEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-14SCHEDULE 13G/ASEC
2026-05-01SCHEDULE 13GSEC
2026-04-22DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-22DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-05SEC
2026-04-22ARSAnnual report to security holders. 2025-12-31SEC
2026-04-21SCHEDULE 13GSEC
2026-04-21SCHEDULE 13G/ASEC
2026-04-01EFFECTEffectiveness filing by commission orderSEC
2026-04-01424B3SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
PERCEPTIVE ADVISORS LLC7.87%
BVF INC/IL7.55%
Affinity Asset Advisors, LLC7.08%
BlackRock, Inc.6.78%
Samsara BioCapital, LLC6.41%
Kynam Capital Management, LP5.27%
ORBIMED ADVISORS LLC4.49%
BALYASNY ASSET MANAGEMENT L.P.4.29%
VANGUARD CAPITAL MANAGEMENT LLC4.19%
EVENTIDE ASSET MANAGEMENT, LLC3.53%

Funds

Fund% owned
Eventide Healthcare & Life Sciences Fund3.53%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.03%
iShares Russell 2000 ETF1.97%
VANGUARD EXTENDED MARKET INDEX FUND1.07%
Fidelity Small Cap Index Fund1.05%
Nuveen Quant Small Cap Equity Fund0.76%
iShares Russell 2000 Value ETF0.59%
VANGUARD RUSSELL 2000 INDEX FUND0.55%
Goldman Sachs Small Cap Equity Insights Fund0.47%
VANGUARD U.S. MOMENTUM FACTOR ETF0.42%

OakChart. STRO. Cached 15 minutes.